Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.
Ronilda D'Cunha, Tofial Azam, Jasmina Kalabic, Toni Anschutz, Adi Lahat, Yinuo Pang
{"title":"Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.","authors":"Ronilda D'Cunha, Tofial Azam, Jasmina Kalabic, Toni Anschutz, Adi Lahat, Yinuo Pang","doi":"10.1007/s40262-024-01462-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>The objective of this study was to characterize the effects of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates in patients with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC) using a cocktail approach.</p><p><strong>Methods: </strong>Patients with CD or UC (n = 20) received single doses of probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) before and after intravenous infusions of risankizumab 1800 mg once every 4 weeks for four doses. Serial blood samples were collected for determination of concentrations of the CYP probe drugs and metabolites with and without risankizumab. Trough samples for risankizumab were collected at sparse timepoints.</p><p><strong>Results: </strong>The point estimates and 90% confidence intervals for maximum plasma concentration (C<sub>max</sub>) and the area under the plasma concentration-time curve from time zero to infinity (AUC<sub>inf</sub>) ratios for the CYP probe substrates administered with risankizumab versus without risankizumab were mostly within the 0.8-1.25 equivalence bounds, except for omeprazole and caffeine. While the upper 90% CI for caffeine AUC<sub>inf</sub> exceeded 1.25, the point estimate was a modest 1.13 and the C<sub>max</sub> ratio was well within 0.8-1.25. For omeprazole, while the lower bound of the 90% CI for AUC<sub>t</sub> (0.715) and AUC<sub>inf</sub> (0.624) extended slightly below the default equivalence limit, the exposures of its metabolite, 5-hydroxy-omeprazole, formed via CYP2C19, were comparable before and after risankizumab treatment, indicating a limited impact of risankizumab. No new safety issues were identified in this study.</p><p><strong>Conclusion: </strong>The totality of data indicated a lack of clinically relevant impact of risankizumab on the evaluated CYP enzymes in patients with CD/UC.</p><p><strong>Clinicaltrials: </strong>GOV: NCT04254783.</p>","PeriodicalId":10405,"journal":{"name":"Clinical Pharmacokinetics","volume":" ","pages":"143-154"},"PeriodicalIF":4.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11762434/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacokinetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40262-024-01462-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objective: The objective of this study was to characterize the effects of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates in patients with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC) using a cocktail approach.
Methods: Patients with CD or UC (n = 20) received single doses of probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) before and after intravenous infusions of risankizumab 1800 mg once every 4 weeks for four doses. Serial blood samples were collected for determination of concentrations of the CYP probe drugs and metabolites with and without risankizumab. Trough samples for risankizumab were collected at sparse timepoints.
Results: The point estimates and 90% confidence intervals for maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve from time zero to infinity (AUCinf) ratios for the CYP probe substrates administered with risankizumab versus without risankizumab were mostly within the 0.8-1.25 equivalence bounds, except for omeprazole and caffeine. While the upper 90% CI for caffeine AUCinf exceeded 1.25, the point estimate was a modest 1.13 and the Cmax ratio was well within 0.8-1.25. For omeprazole, while the lower bound of the 90% CI for AUCt (0.715) and AUCinf (0.624) extended slightly below the default equivalence limit, the exposures of its metabolite, 5-hydroxy-omeprazole, formed via CYP2C19, were comparable before and after risankizumab treatment, indicating a limited impact of risankizumab. No new safety issues were identified in this study.
Conclusion: The totality of data indicated a lack of clinically relevant impact of risankizumab on the evaluated CYP enzymes in patients with CD/UC.
期刊介绍：
Clinical Pharmacokinetics promotes the continuing development of clinical pharmacokinetics and pharmacodynamics for the improvement of drug therapy, and for furthering postgraduate education in clinical pharmacology and therapeutics.
Pharmacokinetics, the study of drug disposition in the body, is an integral part of drug development and rational use. Knowledge and application of pharmacokinetic principles leads to accelerated drug development, cost effective drug use and a reduced frequency of adverse effects and drug interactions.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
